MedTrace Logo

A Efficacy Study of PRX-00023 in Patients With Major Depressive Disorder

NCT00448292 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 330

Last updated 2007-11-14

No results posted yet for this study

Summary

The purpose of this randomized, double-blind, placebo-controlled study is to assess the safety and efficacy of PRX-00023 in patients with major depressive disorder.

Conditions

  • Major Depressive Disorder (MDD)

Interventions

DRUG

PRX-00023

Doses taken two times per day. dose increased at scheduled intervals from 40 mg to 80 mg to 120 mg.

DRUG

Placebo for PRX-00023

Doses taken two times per day. dose increased at scheduled intervals from 40 mg to 80 mg to 120 mg.

Sponsors & Collaborators

  • Epix Pharmaceuticals, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-03-31
Completion
2007-11-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00448292 on ClinicalTrials.gov